Summary
Updated Aug 31, 2026
Robin Shane Readnour is Director of AN2 Therapeutics, Inc. (ANTX). 7 SEC Form 4 filings on record going back to 2024, most recently on 19 August 2026. Most recent open-market trade: sold $112K of ANTX on 19 August 2026. Lifetime open-market purchases: $406K. Lifetime open-market sales: $213K. Historical track record: 2/5 stars across 14 tracked purchases.
Recent Transactions
17Every recent SEC Form 4 transaction Robin Shane Readnour has reported, most recent first.
Track Record
InsiderAlpha computes a forward-return-based score for every insider with enough Form 4 purchase history. The metrics below reflect realized performance after each tracked open-market purchase.
| Metric | Value |
|---|---|
| InsiderAlpha rating | ★★☆☆☆ (2/5) |
| Total purchases tracked | 14 |
| Purchases with forward-return data | 14 |
| 30-day win rate | 29% |
| 90-day win rate | 14% |
| Avg 5-day return | +8.87% |
| Avg 30-day return | -1.24% |
| Avg 90-day return | -9.67% |
| Best 30-day return | +19.81% |
Trading Pattern
InsiderAlpha's records for Robin Shane Readnour go back to 2024: 7 primary Form 4 filings, an average of 2.3 per year. The typical open-market purchase is $29K (14 buys totaling $406K). The largest single buy on record is $78K of ANTX in 2024. Sales side: 2 recorded sales totaling $213K, so the filing history runs buy-heavy by dollar value. 2 recorded transactions carry a Rule 10b5-1 flag, meaning they were pre-scheduled under a written trading plan rather than discretionary.
Other Insiders Active in the Same Stocks
Insiders who reported open-market trades in the last 12 months at the companies Robin Shane Readnour files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Joshua M. Eizen - $53K of ANTX open-market activity in the last 12 months
- Sanjay Chanda - $9K of ANTX open-market activity in the last 12 months
- Lucy Day - $9K of ANTX open-market activity in the last 12 months
- Stephen David Prior - $7K of ANTX open-market activity in the last 12 months
- Sarah Joanne Williams - $2K of ANTX open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Frequently Asked Questions
Who is Robin Shane Readnour?
Robin Shane Readnour is a corporate insider, tracked as Director of AN2 Therapeutics, Inc. (ANTX). InsiderAlpha holds 7 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Robin Shane Readnour submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Robin Shane Readnour been buying or selling stock?
Recorded transactions: 14 open-market purchases ($406K) and 2 open-market sales ($213K) across all tracked filings.
How accurate is Robin Shane Readnour's historical track record?
Across 14 tracked purchases, Robin Shane Readnour averaged -1.2% avg 30-day return with a 29% 30-day win rate. InsiderAlpha rates the track record at 2/5 stars.
Where can I see all of Robin Shane Readnour's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Follow Robin Shane Readnour and every insider like them
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial